Tesofensine (Capsules)

Tesofensine (NS-2330) is a triple monoamine reuptake inhibitor that selectively targets dopamine, norepinephrine, and serotonin reuptake. Initially explored for neurological conditions, it has been studied for effects on monoamine signaling and energy-balance pathways. Tesofensine is studied for its action through unique mechanisms, influencing hypothalamic feeding centers and enhancing satiety signaling while maintaining low stimulant effects. Its profile makes it a valuable compound for metabolic research, obesity modeling, and studies on neurotransmitter dynamics.

In stock

Free Shipping on orders over $200

Tesofensine (NS-2330) is a triple monoamine reuptake inhibitor that selectively inhibits the presynaptic reuptake of dopamine, norepinephrine, and serotonin. Originally investigated for neurological conditions, tesofensine has been examined in clinical research for effects on energy-balance signaling. This compound is studied for its effects on hypothalamic feeding centers and increasing satiety signaling without significant stimulant effects. Research indicates tesofensine enhances fat oxidation while producing minimal increases in heart rate or cortisol compared to structural analogs. Preclinical and clinical investigations support its utility in metabolic research, obesity modeling, and neurotransmitter dynamics research.

Chemical Structure and Identification

  • Compound Name: Tesofensine (NS-2330)
  • Per Capsule: 0.25 mg per capsule
  • Molecular Formula: C₁₇H₂₃Cl₂NO
  • Molecular Weight: 328.28 g/mol
  • CAS Number: 195875-84-4

Research Applications

  • Satiety Signaling Research: Hypothalamic satiety signaling and monoamine transporter modulation [1][2]
  • Energy Balance Research: Body composition and metabolic rate alterations in preclinical models [3]
  • Neurotransmitter Dynamics: Dopamine, serotonin, and norepinephrine reuptake inhibition [2][4]
  • Metabolic Flexibility: Fatty acid oxidation enhancement and fuel substrate utilization [3]
  • Energy Expenditure: Nocturnal metabolic rate and thermogenesis research [1]
  • Obesity Models: Diet-induced obesity reversal and metabolic syndrome pathways [4]

Reference Citations

  1. Astrup A, et al. (2008) – Effect of tesofensine on bodyweight loss in obese patients | https://pubmed.ncbi.nlm.nih.gov/
  2. Billes SK, Cowley MA (2010) – Tesofensine induces appetite suppression via alpha1 adrenoceptor and dopamine pathways | https://pubmed.ncbi.nlm.nih.gov/23932919/
  3. Sjodin A, et al. (2010) – The triple monoamine reuptake inhibitor tesofensine on energy metabolism | https://pubmed.ncbi.nlm.nih.gov/20479765/
  4. Senzacqua M, et al. (2021) – Tesofensine silences GABAergic hypothalamic neurons | https://pmc.ncbi.nlm.nih.gov/articles/PMC11042726/

Important Regulatory Notice

These products are for research use only and are not intended for human consumption, therapeutic use, or diagnostic purposes. All compounds described herein have not been approved by the FDA for human use. These products are strictly intended for in vitro laboratory research and analytical purposes when conducted by qualified research professionals in licensed facilities. Users are responsible for ensuring compliance with all applicable laws regarding purchase and use of these materials.

Important Regulatory Notice

These products are for research use only and are not intended for human consumption, therapeutic use, or diagnostic purposes. All compounds described herein have not been approved by the FDA for human use. These products are strictly intended for in vitro laboratory research and analytical purposes when conducted by qualified research professionals in licensed facilities. Users are responsible for ensuring compliance with all applicable laws regarding purchase and use of these materials.

🎉 Thank you for your order!

Love our products?

Love our products? Join our Affiliate Program and earn 20% commission every time someone purchases through your referral link.

Customer Reviews